SciELO - Scientific Electronic Library Online

 
vol.36 issue2Key aspects in vaccination against COVID-19 in patients with inflammatory bowel diseaseGiant mesenteric cyst. Case report author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista colombiana de Gastroenterología

Print version ISSN 0120-9957On-line version ISSN 2500-7440

Rev. colomb. Gastroenterol. vol.36 no.2 Bogotá Apr./June 2021  Epub Nov 24, 2021

https://doi.org/10.22516/25007440.501 

Report of cases

Histopathologic finding of Strongyloides stercoralis in a patient with Crohn’s disease: Case report

Rubén Gustavo Muñoz-Cedeño1  * 
http://orcid.org/0000-0003-0146-2488

Linda Patricia Naranjo2 
http://orcid.org/0000-0002-3025-1658

Gema Rodríguez3 
http://orcid.org/0000-0002-7772-1186

Virgilio Alvarado-Gallo4 
http://orcid.org/0000-0003-2415-4445

1 Physician, Gastroenteroly Resident, Hospital de Especialidades Dr. Abel Gilbert Pontón. Guayaquil, Ecuador.

2 Physician, Internal Medicine Resident, Hospital Luis Vernaza. Guayaquil, Ecuador.

3 General practitioner, Hospital Universitario de Guayaquil. Guayaquil, Ecuador.

4 Gastroenterologist, Hospital General Guasmo Sur. Guayaquil, Ecuador.


Abstract

Clinical case:

The following is a rare clinical case in an immunocompromised patient with histopathological findings of parasitic infestation. The patient is a middle-aged male who lives in a subtropical area and has a diagnosis of Crohn’s disease treated with corticosteroids and immunomodulators. The patient presented with abdominal pain and chronic anemia for 1 year, with negative laboratory tests for parasites and normal acute phase reactants. Gastroscopy and colonoscopy were performed before the consultation (6 months) without relevant findings. Due to the persistence of the symptoms, endoscopic studies were repeated, finding subepithelial bleeding with histopathological results of Strongyloides stercoralis.

Conclusion:

In the context of an immunocompromised patient living in an endemic area and with a torpid evolution, a differential diagnosis should be made always suspecting a parasitic infestation. Although endoscopy is not necessary to diagnose strongyloidiasis, its use may be convenient.

Keywords: Nematode infections; Strongyloides stercolaris; Immunocompromised host; Hematemesis; Crohn’s Disease

Resumen

Caso clínico:

Se describe un caso clínico poco frecuente en un paciente inmunocomprometido con hallazgo histopatológico de infestación parasitaria. Es un paciente masculino de edad media que habita en zona subtropical con diagnóstico de enfermedad de Crohn tratado con corticoide e inmunomoduladores, presentaba dolor abdominal y anemia crónica de 1 año de evolución, analítica negativa para parásitos, reactantes de fase aguda normales, gastroscopia y colonoscopia previas (6 meses) sin hallazgos relevantes. Por la persistencia del cuadro clínico se repitieron los estudios endoscópicos en los que se visualizaron hemorragias subepiteliales con resultados histopatológicos de Strongyloides stercoralis.

Conclusión:

En el contexto de un paciente inmunocomprometido, en zona endémica y con evolución tórpida, debe obligar a realizar un diagnóstico diferencial en el que se debe sospechar siempre de infestación parasitaria. Aunque la endoscopia no se necesita para el diagnóstico de estrongiloidiasis, su intervención puede ser oportuna.

Palabras clave: Nematodos; Strongyloides stercoralis; inmunocomprometido; hematemesis; enfermedad de Crohn

Introduction

Strongyloides stercoralis colitis is a serious but treatable disease with a high mortality rate if left untreated. It can last for decades and lead to chronic colitis, similar to that observed in inflammatory bowel disease (IBD). Tropical and subtropical areas provide adequate conditions for its development.

Manifestations of infection can vary from asymptomatic eosinophilia in immunocompetent hosts to disseminated disease with septic shock in immunocompromised hosts, as seen in the case presented, with histopathological findings consistent with Crohn’s disease.

Case presentation

This is the case of a 55-year-old male patient, mestizo, businessman, under treatment with corticosteroids and immunomodulators (azathioprine) due to Crohn’s disease. He had a surgical history of appendectomy and cholecystectomy performed in 2015. During a routine check-up for abdominal pain and chronic anemia, he was referred to the emergency room after experiencing intermittent melena for a month, which worsened due to hematochezia, marked pallor, asthenia, and arthralgia for a week. Laboratory tests yielded the following results: hemoglobin: 5.80 g/dL, hematocrit: 18.60%, and platelets: 340 000 mm3 (Table 1). Physical examination showed marked pallor with signs of hemodynamic decompensation and hypotension (blood pressure: 90/40 mm Hg). A probable reactivation of the disease was suspected, so methylprednisolone 60 mg, antibiotics and blood products were administered, achieving clinical improvement. Further laboratory tests included acute phase reactants that were within normal ranges, a stool ova and parasites test, and a stool culture, all of which yielded normal and negative microorganism results. During hospitalization, a gastroscopy was performed and subepithelial hemorrhages, erosions and ulcers were found in the body, antrum, and incisura. Other findings included aberrant pancreas, duodenum with subepithelial hemorrhages up to its second part, and edema. A colonoscopy revealed subepithelial hemorrhages in all its trajectory up to the cecum. For this reason, samples were collected throughout the digestive tract (stomach, small intestine, and colon) (Figures 1 and 2).

Table 1 Laboratory tests on admission 

Test Value obtained
Leukocytes 7.80 x 103/µL
Neutrophils 60 %
Lymphocytes (%) 22 %
Monocytes % 9.40 %
Eosinophils 7.40 %
Basophils 0.40 %
Erythrocytes 2.08 x 104/µL
Hemoglobin 5.80 g/dL
Hematocrit 18.60 %
Platelets 340 000 x103
ESR 15 mm/h
CRP 4 mg/L
Ferritin 150 ng/mL

CRP: c-reactive protein; ESR: erythrocyte sedimentation rate.

Figure 1 Colonoscopy: subepithelial hemorrhages and erosions in the transverse colon. 

Figure 2 Colonoscopy: subepithelial hemorrhages and erosions in the sigmoid colon. 

With the biopsy results pending, 20 days after admission, the patient presented with yellowish liquid stools, diffuse abdominal pain, and fever. An abdominal ultrasound was performed without any relevant finding, while a lab test showed leukocytosis and neutrophilia. The patient also developed fluctuating disseminated pruriginous skin lesions (erythroderma), which were evaluated by the dermatology service with inconclusive skin biopsies, dysphonia, and a cough that resembled laryngotracheitis.

The patient also presented with hypotension: 90/60 mm Hg, tachycardia: 140 beats per minute (bpm), tachypnea: 38 breaths per minute (rpm), hypoxemia: 92 % with oxygen support, highly marked asthenia without data of acute gastrointestinal bleeding, moderate hypotonic dehydration, oliguria, hyponatremia, hypochloremia, and hypoproteinemia without renal response to volume expansion but with preserved sensorium. These data were consistent with systemic inflammatory response syndrome (SIRS), and bacterial or fungal superinfection was suspected. Therefore, it was decided to transfer the patient to the intensive care unit (ICU), but the patient and his relatives disagreed and requested his discharge. The patient was readmitted 8 hours after discharge with acute respiratory distress syndrome (ARDS), severe hypoxemia, and septic shock refractory to inotropic support. The patient eventually died.

The results of the biopsies obtained by endoscopic route were reviewed and showed the presence of S. stercoralis in all samples collected: stomach, duodenum, colon, and rectum.

Discussion

Strongyloidiasis is caused by a nematode called Strongyloides. There are 52 species, but most do not infect humans. The most common and globally distributed human pathogen is S. stercoralis, which affects 100 million people. The other most common species is Strongyloides fueleborni, which is found sporadically in Africa and New Guinea. S. stercoralis is endemic in tropical and subtropical zones, Southeast Asia, Latin America, sub-Saharan Africa, and the southeastern United States, and may be found sporadically in temperate zones1.

This parasite develops into its adult stage in the intestinal mucosa of the duodenum and jejunum. The adult female produces approximately 12 eggs per day, which hatch and release rhabditoid larvae; thus, this disease is only associated with adult females, rhabditoid larvae, eggs, and, very rarely, filariform larvae in the intestinal mucosa. Histopathological changes caused by this disease in the intestinal mucosa were described in 1962 by De Paola, which include intestinal lesions referred to as catarrhal enteritis, edematous enteritis and ulcerative enteritis, depending on the type of inflammatory infiltrate, villous atrophy, and the presence of ulcers2,3.

The presentation and evolution of this infection are determined by the interaction between the host and the parasite. Activation of the T helper 2 (Th2) cellular immune response, humoral immune response, or alteration of the mucosal barrier favor the transformation of the rhabditoid larva into filariform, which is considered an autoinfection syndrome that causes a reinfection in the host itself. When crossing the colon mucosa, the filariform larva can carry bacteria and fungi and distribute them throughout the body, causing bacterial or fungal sepsis and Gram-negative meningitis. This capacity for autoinfection can lead to chronic long-term disease. The respiratory symptoms are caused by larval infiltration of the vascular and alveolar spaces, resulting in pulmonary edema, bronchopneumonia, and alveolar hemorrhage. The death of the parasites inside the lungs causes intense inflammation and ARDS, and mortality can reach up to 80 %4,5.

Dissemination leads to high mortality (70-90 %). Infection with the nematodes. stercoralisis potentially lethal because of its ability to produce devastating autoinfection (hyperinfection/dissemination), particularly in immunosuppressed hosts, such as human immunodeficiency virus (HIV) patients who present with elevated levels of interferon gamma (INF-γ) and decreased serum levels of interleukin 4 (IL-4) and, consequently, immunoglobulin E (IgE), which allows for a more serious disease and the onset of this syndrome2,4,5.

This chronic infection may be clinically inapparent or manifest through skin, gastrointestinal, or pulmonary symptoms, as described in numerous cases of immunosuppression (HIV, alcoholism, organ transplantation, corticosteroid use)6,7 with a high risk of hyperinfection because certain cytotoxic drugs damage cell immunity. The pathophysiology underlying these risk factors, whether disease-related or iatrogenic-induced, is a compromised immune system leading to Th2 helper cell dysfunction; therefore, it is important to detect and eradicate Strongyloides before starting immunosuppressive therapy8.

About one third of patients with strongyloidiasis are asymptomatic. Serum IgE concentration is high in these settings9. Gastrointestinal symptoms include diarrhea, abdominal pain, vomiting, and massive gastrointestinal bleeding secondary to the presence of duodenal ulcers, as well as intestinal occlusion and ileus. Respiratory symptoms include mainly cough and dyspnea. In hyperinfection and dissemination syndromes, pulmonary involvement presents as acute respiratory failure syndrome (ARDS)10-12.

Eosinophilia is correlated with larva migration and may be present in 83 %-92 % of patients with autoinfection; however, it is not observed in all patients, but may be the only clue. It may also be absent in cases of hyperinfection or use of immunosuppressive drugs13,14. For diagnosis, 2 concentrated stool samples should be collected to detect the presence of rhabditiform larvae, and serological tests (enzyme immunoadsorption assay [ELISA] method with immunoglobulin G [IgG] detection), duodeno-jejunal aspiration and stool PCR should be performed15. The presence of eosinophilia on the blood count is expected, leading to the suspicion of a parasite infection; however, when the parasite has spread, there is no eosinophilia, and the white blood cell count is variable. Upper endoscopy is not needed to diagnose strongyloidiasis, although some publications mention that it may give rise to a wide range of endoscopic features16,17.

The reported patient continued treatment with corticosteroids and immunomodulators (azathioprine) for approximately 1 year. In view of the suspicion of reactivation, the administration of corticosteroids at induction doses was started with an apparent improvement, which initially dispelled the suspicion of a parasitic infestation, mainly due to negative serial stool tests and absence of larvae under endoscopic view. The patient received broad-spectrum antibiotics assuming a possible bacterial or fungal superinfection. It should be noted that the requested laboratory tests never showed marked eosinophilia, possibly due to his immunosuppression. The presence of this nematode was confirmed through biopsy results in all samples taken from the stomach, duodenum, and colon. Nevertheless, the torpid evolution and progressive deterioration of the patient prevented the search for atypical microorganisms or studies in the alveolar fluid. In this case, it is not possible to know whether the fatal outcome could have been avoided had the patient received treatment with ivermectin or albendazole given the severity of his condition.

In immunocompromised patients who do not respond to conventional treatment (corticosteroids), it is necessary to look for this type of parasite, especially in areas where the risk or prevalence is higher. Since diagnostic tests may be negative, ivermectin could be administered empirically. Treatment with ivermectin is recommended for uncomplicated strongyloidiasis (grade 1A) and is prescribed as 2 single doses of 200 µg/kg administered over 2 consecutive days. In patients with disseminated disease (hyperinfection), prolonged administration of ivermectin (grade 2C) 200 µg/kg/day for at least 5 to 7 days is suggested, or it may be combined with albendazole 400 mg/orally (VO) 2 times a day for 3 to 7 days. Treatment should be given daily until symptoms resolve and stool tests are negative for at least 2 weeks18-20.

Conclusions

In an immunocompromised patient living in an endemic area with a torpid evolution, negative stool tests and negative acute phase reactants, parasitic infestation should be suspected and empirical treatment with anthelmintic initiated. Moreover, if necessary, endoscopic studies should be repeated since the time of infestation and morphological changes between one study and another cannot be established. Although endoscopy is not necessary for the diagnosis of strongyloidiasis, its use may be convenient, as it was in our case.

References

1. Schär F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. Strongyloides stercoralis: Global Distribution and Risk Factors. PLoS Negl Trop Dis. 2013;7(7):e2288. https://doi.org/10.1371/journal.pntd.0002288Links ]

2. Newberry AM, Williams DN, Stauffer WM, Boulware DR, Hendel-Paterson BR, Walker PF. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest. 2005;128(5):3681-4. https://doi.org/10.1378/chest.128.5.3681Links ]

3. Arévalo Suarez F, Cerrillo Sánchez G. Strongyloides stercoralis: Hallazgos Histopatológicos en Mucosa Duodenal 1999-2005. Rev Gastroenterol Perú. 2006;26(1):44-8. [ Links ]

4. Gorman SR, Craven DE. Images in clinical medicine. Strongyloides stercoralis hyperinfection. N Engl J Med. 2008;359(11):e12. https://doi.org/10.1056/NEJMicm066791Links ]

5. Upadhyay D, Corbridge T, Jain M, Shah R. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Am J Med. 2001;111(2):167-9. https://doi.org/10.1016/s0002-9343(01)00708-2Links ]

6. Woodring JH, Halfhill H 2nd, Reed JC. Pulmonary strongyloidiasis: clinical and imaging features. AJR Am J Roentgenol. 1994;162(3):537-42. https://doi.org/10.2214/ajr.162.3.8109492Links ]

7. Kim JH, Kim DS, Yoon YK, Sohn JW, Kim MJ. Donor-Derived Strongyloidiasis Infection in Solid Organ Transplant Recipients: A Review and Pooled Analysis. Transplant Proc. 2016;48(7):2442-2449. https://doi.org/10.1016/j.transproceed.2015.11.045Links ]

8. Fardet L, Généreau T, Cabane J, Kettaneh A. Severe strongyloidiasis in corticosteroid-treated patients. Clin Microbiol Infect. 2006;12(10):945-7. https://doi.org/10.1111/j.1469-0691.2006.01443.xLinks ]

9. Concha R, Harrington W Jr, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol. 2005;39(3):203-11. https://doi.org/10.1097/01.mcg.0000152779.68900.33Links ]

10. Robinson RD, Lindo JF, Neva FA, Gam AA, Vogel P, Terry SI, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis. 1994;169(3):692-6. https://doi.org/10.1093/infdis/169.3.692Links ]

11. Scowden EB, Schaffner W, Stone WJ. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore). 1978;57(6):527-44. [ Links ]

12. Strazzella WD, Safirstein BH. Asthma due to parasitic infestation. N J Med. 1989;86(12):947-9. [ Links ]

13. Woodring JH, Halfhill H 2nd, Berger R, Reed JC, Moser N. Clinical and imaging features of pulmonary strongyloidiasis. South Med J. 1996;89(1):10-9. https://doi.org/10.1097/00007611-199601000-00002Links ]

14. Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest. 1993;104(1):119-22. https://doi.org/10.1378/chest.104.1.119Links ]

15. Sharifdini M, Mirhendi H, Ashrafi K, Hosseini M, Mohebali M, Khodadadi H, et al. Comparison of Nested Polymerase Chain Reaction and Real-Time Polymerase Chain Reaction with Parasitological Methods for Detection of Strongyloides stercoralis in Human Fecal Samples. Am J Trop Med Hyg. 2015;93(6):1285-91. https://doi.org/10.4269/ajtmh.15-0309Links ]

16. Sreenivas DV, Kumar A, Kumar YR, Bharavi C, Sundaram C, Gayathri K. Intestinal strongyloidiasis--a rare opportunistic infection. Indian J Gastroenterol. 1997;16(3):105-6. [ Links ]

17. Thompson BF, Fry LC, Wells CD, Olmos M, Lee DH, Lazenby AJ, et al. The spectrum of GI strongyloidiasis: an endoscopic-pathologic study. Gastrointest Endosc. 2004;59(7):906-10. https://doi.org/10.1016/s0016-5107(04)00337-2Links ]

18. Drugs for Parasitic Infections. Treatment Guidelines from The Medical Letter. 2013;11(Suppl):e1-e31. [ Links ]

19. Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC Jr, Terashima A, Samalvides F, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016;2016(1):CD007745. https://doi.org/10.1002/14651858.CD007745.pub3Links ]

20. Zaha O, Hirata T, Kinjo F, Saito A, Fukuhara H. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother. 2002;8(1):94-8. https://doi.org/10.1007/s101560200013Links ]

Citation: Muñoz-Cedeño RG, Naranjo LP, Rodríguez G, Alvarado-Gallo V. Histopathologic finding of Strongyloides stercoralis in a patient with Crohn’s disease: Case report. Rev Colomb Gastroenterol. 2021;36(2):252-256. https://doi.org/10.22516/25007440.501

Funding sources None declared by the authors.

Received: January 23, 2020; Accepted: April 08, 2020

*Correspondence: Rubén Gustavo Muñoz-Cedeño. drubenmunoz@gmail.com

Conflicts of interest

None declared by the authors.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License